Echo Therapeutics, Ferndale Pharma launch drug-device trial

April 27, 2010 By MassDevice staff Leave a Comment

Echo Therapeutics Inc. (OTC:ECTE) and Ferndale Pharma Group Inc. enrolled the first patients in a clinical trial of Echo’s Prelude SkinPrep device and Ferndale’s 4 percent topical lidocaine, ahead of an application for 510(k) clearance for the drug-device combo from the Food & Drug Administration.

Franklin, Mass.-based Echo’s Prelude device is a needle-free, transdermal drug delivery system that ablates a thin layer of skin before a drug is applied.

In January the company said it was nearly ready to launch the clinical trial, having completed its development work on the product. The trial is designed to "evaluate the ability of the Prelude SkinPrep System to ablate the skin prior to application of OTC 4 percent lidocaine cream for local dermal anesthesia," according to a press release. Once it’s complete the companies plan to submit the 510(k) application to the FDA, likely later this year.

Echo said it licensed the rights to develop and commercialize the Prelude in the U.S. and the U.K. to Ferndale in May 2009, for an up-front payment of $750,000. Once the device wins FDA clearance another $750,000 milestone payment is due, plus $12.5 million "in milestone payments and guaranteed minimum royalty payments" and ongoing royalties on net sales, according to the release.

Echo chairman and president Dr. Patrick Mooney estimated in prepared remarks that the topical anesthetic market is worth more than $200 million a year and that the Prelude device "has the potential to grow it significantly."

Echo is also nearing readiness for a clinical trial of its Symphony tCGM transdermal glucose monitor, after a design breakthrough reduced the size of the device’s electrical component by a third.

Echo pulled in about $3.5 million in new investments late last year, $3 million from a private stock sale in November and another $562,000 from a group of backers in Philadelphia in December.

Registration is Open for DeviceTalks Boston

Registration is open for DeviceTalks Boston! Join us on June 5-6, 2019, as we explore the trends and technology that are shaping the future of the medical device industry.

REGISTER NOW

Carbon debuts dental technology platform
3D printing company Carbon unveiled an integrated technology platform for the dental market last week at the International Dental Show in Cologne, Germany. The platform combines software, hardware and materials in an end-to-end solution designed to meet the needs of dental and orthodontic labs and enable them to scale quickly and economically, according to the… […]
This drug sponge could reduce cancer treatment side effects
Researchers from the University of California Berkeley have developed sponges that, when injected into the bloodstream, can absorb excess drugs. The drug sponge is made from an absorbent polymer coating and is 3D printed to precisely fit veins that carry the blood flowing out of a targeted organ. The sponge could then absorb any leftover… […]
Nyxoah sleep apnea nerve-stim therapy gains CE Mark
Nyxoah said it has won the CE Mark for its novel hypoglossal nerve stimulation therapy for treating obstructive sleep apnea (OSA). The Genio system is a battery-free, leadless and minimally invasive neurostimulator designed to deliver bilateral hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea patients who have failed conventional continuous positive airway pressure… […]
Ex-NuVasive CEO Lucier to head new M&A firm Corza Health
Recently departed NuVasive (NSDQ:NUVA) CEO Gregory Lucier will lead a new company formed to acquire medtech and life sciences firms and assets. Lucier, 54, is partnering with Chicago-based private equity firm GTCR to form the new company, Corza Health, in San Diego. GTCR holds stakes in Regatta Medical, which owns laser micro manufacturer Resonetics and… […]
Steute Meditech touts medical-grade foot switches
Steute Meditech has launched a new line of wireless, medical-grade foot switches. The wireless switches operate on 2.4 GHz by using spread-spectrum frequency-hopping technology. They are also designed for medical applications with a number of safety functions that allow for the operation of several wireless systems in one transmission zone. Steute Meditech’s new foot switch… […]
Gottlieb wants to fix clinical trials before departing FDA
The FDA has issued new draft guidance to protect human subjects of clinical trials and the data these trials generate. The draft guidance on using a risk-based approach to conducting clinical trials is one of a handful of guidances promulgated by the agency since FDA commissioner Dr. Scott Gottlieb announced his upcoming departure. In a… […]
Toray touts polymer for regenerative medicine
Toray Industries (Tokyo) recently announced that it has created a novel bioabsorbable polymer with skin-like flexibility. Proprietary functional polymer design technology allows the polymer to recover its original shape even after being stretched 10 times the original length, the company explained in a March 14 announcement. Toray also has identified a way to improve the… […]
Thornhill Medical’s ‘simple’ device may save lives
Thornhill Medical’s device to help patients suffering from carbon monoxide poisoning has won de novo clearance from the FDA. Carbon monoxide poisoning occurs when carbon monoxide attaches to the hemoglobin in the blood exactly where oxygen is supposed to attach, reducing the amount of oxygen carried to the brain and other tissues. Toronto-based Thornhill Medical’s… […]
Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. DeviceTalks is excited to announce that Tyler Shultz will be the closing keynote speaker at DeviceTalks Boston. Shultz will take attendees behind the story that everyone… […]
Study shows catheter ablation for Afib significantly boosts quality of life
Patients who had catheter ablation for atrial fibrillation (Afib) had fewer symptoms, a significant long-term improvement in quality of life and fewer recurrences and hospitalizations than those who received drug therapy alone, according to a government-funded study. The same study showed that catheter ablation appeared no more effective than drugs in preventing strokes, deaths, and… […]
Medical device cybersecurity: It’s time to get real
Medical device makers, regulators and healthcare delivery organizations are increasingly working together to strengthen cybersecurity. But are they doing enough? Almost no one in the medtech industry disputes the vulnerability posed by cyberattacks. How to go about boosting security is another matter – one on which those stakeholders have recently stepped up their collaboration. One… […]